Scholarlink

<p>RRAS2, induced by H3 lysine 18 lactylation (H3K18la), plays a vital role in activating signal transduction pathways that control cell proliferation. However, fewer studies focused on the role of H3K18la-mediated RRAS2 in head and neck squamous cell carcinoma (HNSCC). The RRAS2 expression was obtained from various databases, and we explored the role of RRAS2 in HNSCC prognosis. We further investigated the roles of RRAS2 in the immune microenvironment and drug resistance. The roles of RRAS2 in HNSCC progression were also determined. We suggested that RRAS2 was overexpressed in various cancer types, including HNSCC. High expression of RRAS2 might play a vital role in HNSCC metastasis and prognosis. In addition, RRAS2 might mediate the infiltration of various immune cells in HNSCC. High RRAS2 expression was positively related to chemotherapy resistance and tumor mutation burden (TMB), a biomarker for poor immunotherapy response. Furthermore, we revealed that RRAS2 expression was mediated by H3K18la, and RRAS2 played a crucial role in HNSCC malignant progression. Moreover, high expression of RRAS2 might activate HNSCC-associated KEGG pathways and therapy resistance. In summary, H3K18la-induced RRAS2 was associated with HNSCC prognosis, and played a crucial role in immune infiltration, chemotherapy resistance and invasion, suggesting that H3K18la-RRAS2 axis might be a novel candidate therapeutic target for HNSCC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

H3 lysine 18 lactylation-mediated RRAS2 facilitates migration and invasion of head and neck squamous cell carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Shenghong Miao,
  • Lin Lin,
  • Menghong Long,
  • Yi Fu

摘要

RRAS2, induced by H3 lysine 18 lactylation (H3K18la), plays a vital role in activating signal transduction pathways that control cell proliferation. However, fewer studies focused on the role of H3K18la-mediated RRAS2 in head and neck squamous cell carcinoma (HNSCC). The RRAS2 expression was obtained from various databases, and we explored the role of RRAS2 in HNSCC prognosis. We further investigated the roles of RRAS2 in the immune microenvironment and drug resistance. The roles of RRAS2 in HNSCC progression were also determined. We suggested that RRAS2 was overexpressed in various cancer types, including HNSCC. High expression of RRAS2 might play a vital role in HNSCC metastasis and prognosis. In addition, RRAS2 might mediate the infiltration of various immune cells in HNSCC. High RRAS2 expression was positively related to chemotherapy resistance and tumor mutation burden (TMB), a biomarker for poor immunotherapy response. Furthermore, we revealed that RRAS2 expression was mediated by H3K18la, and RRAS2 played a crucial role in HNSCC malignant progression. Moreover, high expression of RRAS2 might activate HNSCC-associated KEGG pathways and therapy resistance. In summary, H3K18la-induced RRAS2 was associated with HNSCC prognosis, and played a crucial role in immune infiltration, chemotherapy resistance and invasion, suggesting that H3K18la-RRAS2 axis might be a novel candidate therapeutic target for HNSCC.